JUMP REPORT
Avg Daily Volume: 795,234 Market Cap: 812.56M
Sector: Services Short Interest: 14.11
EARNINGS EXPECTATIONS:
THIS QTR: EPS: .03/share REV: 37.99/M
___________________________________________________________
LAST QTR: EPS: .01/share ACTUAL: .04/share (BEAT)
____________________________________________________________
NEXT QTR: EPS: .01/share REV: 38.9/M
______________________________________________________
FULL YR: EPS: .13/share REV: 164.68/M
______________________________________________________
*These are the base metrics we will be watching against the actual release numbers
__________________________________________________________________
BEAT/MISS RECORD: –% OF THE TIME THEY BEAT ESTIMATES
PRIOR ‘JUMP ZONE’ MOVES (LAST 3 QTRS %) -13.59, 9.11, 12.55
EXPECTED JUMP MOVE: 10-15%
——–
*** With market volatility at extremes during the coronavirus pandemic there is greater risk in trading these events which may not react as they would under normal market conditions. Please take extra caution before trading.
Links To Latest News and Headlines
Leading transplant clinicians to present data in seven abstracts at International Society of Heart and Lung Transplantation Annual MeetingSOUTH SAN FRANCISCO, Calif., April 22, 2021 (GLOBE NEWSWIRE) — CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced that experts will be presenting 22 clinical abstract presentations at the International Society of Heart and Lung Transplantation (ISHLT) Annual Meeting & Scientific Sessions, to be held between April 24-28, 2021. Abstracts will focus on AlloSure Lung, the company’s unique and proprietary surveillance technology for lung transplant patients. The new research, many from large multicenter prospective studies, demonstrates the validity and use of CareDx’s AlloSure in lung transplantation. These important studies extend this technology for donor derived cell-free DNA (dd-cfDNA) that has already been proven in heart and kidney transplant patients. The new data will be presented during virtual abstract sessions and a virtual symposium by leaders in the field of lung transplantation. “We are thrilled to be sharing this new data with our colleagues at ISHLT. AlloSure Lung will undoubtedly change the way that we manage the care of our lung transplant patients, helping us to non-invasively rule-out allograft injury related to allograft rejection or CLAD,” said Brian Keller, M.D., Ph.D., The Ohio State University Wexner Medical Center. “Lung transplant recipients have one of the highest incidences of acute rejection, with only half of grafts surviving five years post-transplant,” said Reg Seeto, President and CEO, CareDx. “We are so excited to share the data on AlloSure Lung. The seven lung presentations will cover a variety of evidence-based clinical results supporting the clinical utility of AlloSure in this population.” The following AlloSure Lung abstracts will be presented: Early Phase Circulating Donor-Derived Cell-Free DNA in Patients after Lung Transplantation – K. Noda, University of Pittsburgh Medical CenterCell-Free DNA Tissue Damage Mapping in Transplant Patients Infected with COVID-19 – T. E. Andargie, Genomic Research Alliance for Transplantation (GRAfT) and Laboratory of Applied Precision Omics, National Heart, Lung, and Blood Institute (NHLBI)Cell-Free DNA to Monitor Immunosuppression Adequacy in Lung Transplantation – A. Charya, Genomic Research Alliance for Transplantation (GRAfT)Cell Free DNA Levels in Patients with Acute Rejection after Lung Transplantation – I. Timofte, University of Maryland Medical CenterTelemedicine with a Cell-Free DNA Based Monitoring Approach Maintains Lung Allograft Function While Reducing Frequency of Invasive Bronchoscopy – P. Shah, Johns Hopkins UniversityBiological Variation of Donor-Derived Cell-Free DNA in Lung Transplant Recipients – M. B. Keller, National Institutes of Health, BethesdaA Longitudinal Assessment of Donor Derived Cell Free DNA in Lung Transplant Recipients – J.B. Smith, Department of Medicine, University of Colorado In addition, CareDx will host its lung symposium: “AlloSure Lung: Donor-Derived Cell-Free DNA as an Innovative Biomarker for Lung Transplant Patients,” on Monday, April 26th, 9:30 a.m. to 10:30 a.m. Eastern. Speakers include:Deborah Levine, M.D., University of Texas, San Antonio Health SystemKiran Khush, M.D., Stanford Health CareSam Weigt, M.D., UCLA HealthPali Shah, M.D., Johns Hopkins MedicineBrian Keller, M.D., Ph.D., The Ohio State University Wexner Medical Center In addition to its seven lung abstracts, CareDx is honored to also have had 15 heart abstracts accepted for presentation at ISHLT.About CareDxCareDx, Inc., headquartered in South San Francisco, California, is a leading precision medicine solutions company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com. CONTACTS:CareDx, Inc.Sasha KingChief Marketing Officer415-287-2393sking@caredx.com Investor RelationsGreg Chodaczek347-610-7010investor@caredx.com
SOUTH SAN FRANCISCO, Calif., April 21, 2021 (GLOBE NEWSWIRE) — CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced it will report financial results for the first quarter 2021 after market close on Wednesday, May 5, 2021. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Individuals interested in listening to the conference call may do so by dialing 877-705-6003 for domestic callers or 201-493-6725 for international callers. Please reference Conference ID: 13718586. To listen to a live webcast, please visit the investor relations section of CareDx’s website at: investors.caredxinc.com. About CareDxCareDx, Inc., headquartered in South San Francisco, California, is a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com. CONTACTS:Greg Chodaczek347-620-7010investor@caredx.com
Virtual Events to Highlight New Data and AlloSeq Solutions for European Labs and CliniciansSOUTH SAN FRANCISCO, Calif., April 20, 2021 (GLOBE NEWSWIRE) — CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced it will be hosting two symposia to share the latest data on CareDx products at the 2021 European Federation for Immunogenetics and Histocompatibility Conference (EFI), together with the British Society for Histocompatibility and Immunogenetics (BSHI), which will take place between April 21-23, 2021. The conference is an opportunity to present the latest in HLA typing and post-transplant surveillance data. The CareDx symposia will be available online via the EFI platform for viewing any time during the conference. The first symposium, titled “Changing the Paradigm of HLA Typing: Better Matching, Better Method,” includes: Reduced PCR-Induced Errors from a Hybrid Capture-Based NGS Assay for HLA Typing – Nicholas Brown, University of PennsylvaniaSignificance of High Resolution HLA Typing in Solid Organ Transplantation – Nils Lachhman, Charité-Universitätsmedizin, Berlin, GermanyAllelic typing for Epitope Matching in Transplantation – Eric Spierings, University Medical Center, Utrecht, Netherlands “The CareDx sessions at the EFI meeting this year will tackle innovative subjects in the field of Immunogenetics and Transplantation, which will have great impact on improving patient care and transplant outcomes!” said Moheeb Al-Awwami, Director, Histocompatibility and Immunogenetics Laboratory, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia. The second symposium, “Changing the Transplant Care Paradigm – Cutting-Edge Technologies for Post-Transplant Surveillance,” includes: Donor-Derived Cell-Free DNA as Biomarker to Assess Active Rejection & Treatment Response in Kidney Allografts – Caner Süsal, University of Heidelberg, GermanyValue of dd-cfDNA as a Surveillance Biomarker in Heart Transplant – Maria Generosa Crespo-Leiro, Complexo Hospitalario Universitario A Coruña (CHUAC), SpainQuality Approach and Adoption of NGS based Chimerism Solution in a French Laboratory – Mathilde Cherel, EFS Rennes, Blood Bank of Brittany, France In addition, CareDx will be well-represented throughout EFI in bringing new innovation. “We are excited to be sharing a record 8 abstracts and 1 oral presentation at EFI as we showcase leadership in innovation with our AlloSeq and QTYPE portfolios,” said Reg Seeto, President and CEO, CareDx. “Transplantation is global, and we at CareDx are committed to improving the transplant patient journey.” Oral Presentation: 4th field resolution typing of HLA-H is critical for defining the MHC haplotype structure between HLA-F and HLA-E: Implications for matching in HSCT – Peter B. Dallas, et al.A streamlined AlloSeq Tx hybrid capture workflow: DNA to sequencing in a single day – Supaneda N. Kolanski, et al.Optimization of mixed pools of buccal and peripheral blood DNA for routine testing with AlloSeq Tx 17 hybrid capture – Lindsey T. Madden, et al.New insights into MHC variability and reporting HLA homozygosity with AlloSeq Tx 17, a hybrid capture method for HLA typing – Christopher N. Newbound, et al.AlloSeq Tx genotyping using DNA extracted from saliva – Supaneda N. Kolanski, et al.Genetic risk factors in solid organ transplantation: beyond classical human leukocyte antigen – Beata Kmiec, et al.Accurate, Reproducible and Sensitive Chimerism Monitoring with NGS-based AlloSeq HCT – Camila Egidio, et al.Intra-Laboratory Evaluation of a Next-Generation Sequencing-Based Solution for Chimerism Monitoring – Ina Skaljic, et al.Laboratory validation of CE-marked AlloSeq cfDNA to measure donor-derived cell-free DNA in transplant patients – Thierry Viard, et al. About CareDxCareDx, Inc., headquartered in South San Francisco, California, is a leading precision medicine solutions company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com. CONTACTS:CareDx, Inc.Sasha KingChief Marketing Officer415-287-2393sking@caredx.com Investor RelationsGreg Chodaczek347-610-7010investor@caredx.com
Company to showcase its latest integrated solutions for improving care across the whole transplant journeySOUTH SAN FRANCISCO, Calif., April 16, 2021 (GLOBE NEWSWIRE) — CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced it will be exhibiting at the 29th Annual UNOS Transplant Management Forum (TMF), which takes place virtually between April 19-22, 2021. On April 20, 2021 at 11:00 a.m. EDT, CareDx will be hosting a symposium titled “Providing Personalized Care for Every Step on the Transplant Journey,” which will include the following topics: The Transplant PatientPre-transplant Care with TX Connect and XynCare Quality Care with XynQAPI Post-transplant Care with AlloSure® dd-cfDNA “CareDx is thrilled to join TMF this year and share its comprehensive suite of integrated digital solutions that provide better tools for those who care for transplant patients,” said Kashif Rathore, Senior Vice President, Digital Business, CareDx. “With the recent inclusion of TX Connect into the CareDx family, we now offer solutions at every critical step of the transplant patient journey—from transplant referral to post transplant care.” About CareDxCareDx, Inc., headquartered in South San Francisco, California, is a leading precision medicine solutions company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com. CONTACTS:CareDx, Inc.Sasha KingChief Marketing Officer415-287-2393sking@caredx.com Investor RelationsGreg Chodaczek347-610-7010investor@caredx.com
Initial projects underway for global pharmaceutical companySOUTH SAN FRANCISCO, Calif., April 08, 2021 (GLOBE NEWSWIRE) — CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced that they have launched a fully-functional next generation sequencing (NGS) HLA typing service lab in Stockholm, Sweden to support companies in research and academic studies working on HLA applications in vaccine and drug development as well as disease association studies. The CareDx HLA typing service powered by AlloSeq Tx17 enables best-in-class research by using innovative hybrid-capture technology with the highest level of resolution, no long-range PCR inefficiencies, and a fast turnaround time. AlloSeq Tx17 provides over 50% more gene content than other NGS solutions on the market, including 11 classical HLA loci as well as HLA-E, -F, -G, -H, MICA, and MICB. CareDx’s HLA typing service in Stockholm has been engaged by one of the top 10 global pharmaceutical companies in the world, providing initial testing results in the first quarter of 2021. “This is an exciting time for CareDx – we are not only expanding our capabilities but also investing in our global team to provide a first ever CareDx testing service outside the United States,” said Alexander Johnson, SVP, Products, Cell Therapy and Business Development, CareDx. “This expansion allows us to partner with those at the forefront of drug development research and support improved care for even more patients around the world.” For more information on HLA typing services in Europe, please contact hlatypingservice@caredx.com About CareDxCareDx, Inc., headquartered in South San Francisco, California, is a leading precision medicine solutions company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com. CONTACTS:CareDx, Inc.Sasha KingChief Marketing Officer415-287-2393sking@caredx.com Investor RelationsGreg Chodaczek347-610-7010investor@caredx.com
StockJumpers analysis and trade plans are uploaded generally 1 HOUR BEFORE MARKETS CLOSE (3PM EST) for most events.
“I’m sorry, this content is for members only. To access this content, you must log in with your membership credentials – OR if you are not a member yet, visit our registration page here and get signed up Looking forward to having you on-board ASAP”
There is a significant amount of data behind the scenes involved in the analysis and trade plan tab above, that does not get put into the report. Too much information for traders often confuses things – so this is stripped down to only what is needed to make the best possible decision(s) on trading the trajectory.
NOTICE: All data on this site has been published for informational and educational purposes only and does not constitute an offer to sell nor a solicitation of an offer to buy any security which may be referenced here or in our websites. StockJumpers is not an Investment Adviser and relies on the publisher’s exemption as defined in Section 401(f) of the Uniform Securities Act, and provides no personal advice or recommendations. The services and published information contained herein is for non-commercial, educational use and display. StockJumpers and any of its affiliates does not represent that the securities or services discussed are suitable for any investor. You should assume that StockJumpers and or its management has or will take a position in the stock, whether it is stated or not. You are further advised not to rely on any information contained in this report and associated websites in the process of making a fully informed investment decision. Trading is risky and you can lose your investment. For the complete risk disclosure and other legal information please review the full Terms of Use Agreement.